01 December 2025
01 December 2025
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
The proportion of children receiving a second dose of the MMR vaccine is still below the threshold to stop viral transmission.
Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for Eylea HD.
Armlupeg is indicated to reduce infection risk, specifically febrile neutropenia, in non-myeloid cancer patients.
If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.
With an eye on 2026, the healthcare editorial team reflects on key takeaways and trends from recent pharma conferences.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
